Bausch+Lomb Investor Conference Presentation Deck
2022 Bausch + Lomb Business Fundamentals are Strong
5% organic revenue growth ¹,2 YTD 22 vs. YTD216;
6 consecutive quarters of organic revenue growth ¹,2,7
Strong performance in key franchises:
Ocuvite® + PreserVision®: +9% reported revenue growth YTD
• LUMIFY®: -50% market share in Redness Reliever Category
Bio True ONEday: +4% reported revenue growth YTD
Bausch+Lomb ULTRA®: +5% reported revenue growth YTD
Daily SiHy: +32% reported revenue growth YTD
VYZULTA®: +32% TRx growth in FY22 vs. FY21⁹
• Consumables: +4% reported revenue growth YTD
Implantables: +4% reported revenue growth YTD
●
.
FDA filing acceptance for NOV03 and 510(k) Clearance from FDA
for Bio True® Hydration Boost Contact Lens Rehydrating Drops
Enhanced our pipeline since the IPO with increased R&D spend
(+14% YTD22 through Q3) and completed 5 acquisitions/licensing transactions
BAUSCH + LOMB
BLCO was the largest healthcare IPO in 2022 and the
4th largest IPO overall in 2022
Launched new products including:
• XIPEREⓇ
• REVIVEⓇ
Project Watson®
Geo-expansion for
LUMIFY® and VYZULTAⓇ
The Most
Integrated Eye
Care Company³
3. Peers consist of: Alcon, Johnson & Johnson, CooperVision, Carl Zeiss Meditec AG. Hoya, Rayner, Regeneron, Allergan and Novartis.
4. Period 2018-2021. Internal and peer data. Global leader based on reported peer group revenue. Peer group includes: Alcon. Allergan, Prestige and Johnson & Johnson.
5. Based on reported revenue.
6. As of Sept. 30 and noted in the 3022 BLCO earnings presentation.
7. Q221-Q322
8. IRI Panel Omnichanne
9. IQVIA NPA weekly.
Bio True® Hydration Plus
Multi-Purpose Solution
• Enhanced Ocuvite® Adult 50+ Eye
Vitamin Formulation with Vitamin D
Bausch + Lomb is....
1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.
Global leader
in Consumer
Eye Health 4
#3 Largest
Eye Health
Company5
10View entire presentation